News

Life science research distributor Nordic BioSite Group acquires Austrian Szabo Scandic to further expand geographical footprint – with ultimate goal of becoming an even stronger partner to its suppliers and customers.

We offer an extensive range of research reagents to support the SARS-CoV-2 studies. Please see below the products for SARS-CoV-2 research, from antibodies to proteins and additional reagents like viral transport medium or ELISA kit to measure cytokine storm. For the detection of SARS-CoV-2, we have ELISA and PCR kits as well as an antibody rapid test.

Nordic-MUbios’ mouse anti double-stranded RNA antibody (clone J2) was used in crucial research to identify potent therapeutic agents to impede SARS-CoV-2 viral entry into host cells. SARS-CoV-2, better known as COVID-19, is a positive-strand RNA virus.

Serum-free cell culture is a cutting-edge topic in research. Find out here where the advantages of this access lie and what you should pay attention to.

Ever-evolving biological research requires tools that are not always easily and commercially available. For a researcher, that challenge can be difficult for a variety of reasons: material procurement, technical knowledge, capacity and the risk of production downtime.

When was the last time you tested? Not yourself, but your cell culture? Mycoplasma contamination is a well-known but still often ignored problem in cell culture. Currently, only about 30% of cell culture labs test for mycoplasma.

90 drugs received marketing authorization in the EU in 2020, and a further 27 in the first quarter of 2021. The majority of therapies were registered in the field of oncology – comparable to previous years. However, Covid-19 reversed this trend. In 2021, private and public research institutions in Austria expect a particularly large number of publications on vaccines and drugs for infectious diseases.

Team AstraZeneca or Team Biontech Pfizer? On social media, many happily vaccinated people are showing off their vaccination status and proudly displaying the vaccine they received. And the pictures are representative of the debate about whether mRNA or vector vaccines are better.

A disease is considered rare if it affects no more than 5 in 10,000 inhabitants. That doesn't sound like much. But a total of about 8,000 rare diseases are known worldwide.

With the first Immunis Sponsorship for Young Science, or Immunis for short, SZABO-SCANDIC and the Next Generation Immunologists NGI, as the young scientists' organization of the Austrian Society for Allergology and Immunology ÖGAI is called, want to support young scientists.